Search

Displaying results 9591 - 9600 of 10000 in total
  1. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology. It provides patients with long term therapeutic benefit from a single administrat...

  2. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase I trials. It is expected...

  3. Drug

    HMR4011

    go.drugbank.com/drugs/DB06225
    Experimental

    HMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid. IPL 576,092 has previously been investigated as a treatment for asthma.

  4. Drug

    MAHDL01

    go.drugbank.com/drugs/DB06270
    Experimental

    MAHDL01 is a pharmaceutical combination of whole plants, which is used to increase the HDL/LDL ratio that improves overall cardiovascular health.

  5. Drug

    Semuloparin

    go.drugbank.com/drugs/DB06294
    Investigational

  6. Drug

    R107474

    go.drugbank.com/drugs/DB06553
    Experimental

  7. Drug

    P-57AS3

    go.drugbank.com/drugs/DB06569
    Experimental

  8. Drug

    Enokizumab

    go.drugbank.com/drugs/DB05555
    Investigational

    A humanized immunoglobulin G1k anti-interleukin-9 mAb.

  9. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been disc...

  10. Drug

    SJG-136

    go.drugbank.com/drugs/DB11965
    Investigational

    SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and